Christopher G. Nasveschuk

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Brian K. Albrecht, Victor Gehling, Michael C. Hewitt et al. · Journal of Medicinal Chemistry · 2016 · 214 citations · Full text

Immunology, Pharmacotherapy, Tumor Biology +22

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 214 citations · Full text

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon et al. · Chemistry & Biology · 2013 · 154 citations

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +8

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

William D. Bradley, Shilpi Arora, Jennifer Busby et al. · Chemistry & Biology · 2014 · 148 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains

Terry D. Crawford, Vickie Tsui, E. Megan Flynn et al. · Journal of Medicinal Chemistry · 2016 · 117 citations · Full text

Molecular Biology, Chemical Biology, Pharmaceutical Chemistry +17